Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China
ObjectiveAzole antifungals inhibit the enzyme cytochrome P450 3A4 (CYP 3A4), increasing venetoclax (VEN) levels and the risk of serious adverse reactions. Dose adjustments for VEN with voriconazole (VOR) vary in studies. The drug-drug interactions (DDI), safety and economic implications of VEN with...
Saved in:
| Main Authors: | Rongrong Wang, Yanfen Li, Ran Zhang, Yuan Ren, Yifan Liu, Tianlin Wang, Jin Wu, Xiangjin Zheng, Shu Li, Yu Jing |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1539233/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Population Pharmacokinetics Study of Venetoclax Concomitant with Voriconazole in Patients with Hematologic Malignancies
by: Yang J, et al.
Published: (2025-05-01) -
Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01) -
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review
by: Xiaohong Liu, et al.
Published: (2025-08-01) -
Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study
by: Ji-Xin Tian, et al.
Published: (2025-07-01) -
A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia
by: Brunno Gilberto Santos de Macedo, et al.
Published: (2025-04-01)